250,065 Shares in Dyne Therapeutics, Inc. $DYN Bought by Fisher Asset Management LLC

Key Points

• Fisher Asset Management initiated a new stake in Dyne Therapeutics, buying 250,065 shares worth about $4.89 million in the fourth quarter. The position represented 0.18% of the company’s shares outstanding in its latest SEC filing.
• Dyne Therapeutics shares were up 2.2% to $18.56, leaving the company with a market cap of about $3.07 billion. The stock remains well below its 52-week high of $25.00 but above its 52-week low of $8.06.
• The company’s latest earnings beat expectations, reporting EPS of -$0.73 versus analysts’ forecast of -$0.77. Analyst sentiment is still generally positive, with a Moderate Buy consensus and an average target price of $35.00.

Fisher Asset Management LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 250,065 shares of the company's stock, valued at approximately $4,891,000. Fisher Asset Management LLC owned 0.18% of Dyne Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC purchased a new stake in Dyne Therapeutics in the third quarter worth $30,000. Strs Ohio purchased a new stake in Dyne Therapeutics in the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company's stock worth $70,000 after purchasing an additional 1,109 shares during the period. Tower Research Capital LLC TRC grew its stake in Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company's stock worth $100,000 after purchasing an additional 7,697 shares during the period. Finally, Prudential Financial Inc. purchased a new stake in Dyne Therapeutics in the second quarter worth $111,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Trading Up 2.2%

NASDAQ DYN opened at $18.56 on Friday. The stock has a market cap of $3.07 billion, a P/E ratio of -5.76 and a beta of 1.08. The stock's fifty day moving average price is $18.27 and its 200-day moving average price is $18.31. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.04. During the same period in the prior year, the business posted ($1.05) earnings per share. As a group, equities analysts forecast that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox sold 3,311 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $60,789.96. Following the sale, the chief executive officer directly owned 370,834 shares of the company's stock, valued at $6,808,512.24. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Douglas Kerr sold 1,564 shares of the stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $28,715.04. Following the sale, the insider directly owned 170,042 shares in the company, valued at $3,121,971.12. This trade represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders bought 7,500 shares of company stock valued at $124,400 and sold 1,559,462 shares valued at $29,814,746. 14.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Wall Street Zen raised Dyne Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 16th. HC Wainwright cut their target price on Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 3rd. Morgan Stanley cut their target price on Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating on the stock in a research note on Monday, March 2nd. Jefferies Financial Group reissued a "buy" rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, Sanford C. Bernstein increased their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a research note on Wednesday, May 13th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.00.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.